Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBT Margin (2016 - 2025)

Cumberland Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 10.18% for Q4 2025.

  • For Q4 2025, EBT Margin rose 859.0% year-over-year to 10.18%; the TTM value through Dec 2025 reached 6.31%, up 1076.0%, while the annual FY2025 figure was 6.31%, 1076.0% up from the prior year.
  • EBT Margin for Q4 2025 was 10.18% at Cumberland Pharmaceuticals, up from 23.44% in the prior quarter.
  • Across five years, EBT Margin topped out at 10.7% in Q1 2025 and bottomed at 52.59% in Q4 2021.
  • The 5-year median for EBT Margin is 11.08% (2024), against an average of 11.69%.
  • The largest annual shift saw EBT Margin crashed -3527bps in 2021 before it soared 3296bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 52.59% in 2021, then skyrocketed by 50bps to 26.43% in 2022, then skyrocketed by 60bps to 10.47% in 2023, then crashed by -79bps to 18.77% in 2024, then surged by 46bps to 10.18% in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EBT Margin are 10.18% (Q4 2025), 23.44% (Q3 2025), and 6.73% (Q2 2025).